WilmerHale Advises Orna Therapeutics on $221M Series B Financing

WilmerHale Advises Orna Therapeutics on $221M Series B Financing

Client News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On August 16, 2022, Orna Therapeutics, a biotechnology company pioneering a new investigational class of engineered circular therapies, announced that it secured $221 million in a Series B funding round with contributions from Merck, with whom Orna entered into a collaboration agreement, and founding investors MPM Capital and BioImpact Capital. The financing will enable Orna to continue development of its circular lipid nanoparticle delivery platform and expand the reach of current RNA therapeutics.

The team representing Orna in its Series B financing was led by Rosemary G. Reilly, Rebecca Nauta, Jenna Ventorino, Nick Andreacchi, Meghan Walsh and Bill Caporizzo.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel